These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31188806)

  • 1. New approaches to immunotherapy for metastatic castration-resistant prostate cancer.
    Subudhi SK
    Clin Adv Hematol Oncol; 2019 May; 17(5):283-286. PubMed ID: 31188806
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
    Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
    Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes.
    Claps M; Mennitto A; Guadalupi V; Sepe P; Stellato M; Zattarin E; Gillessen SS; Sternberg CN; Berruti A; De Braud FGM; Verzoni E; Procopio G
    Cancer Treat Rev; 2020 Aug; 88():102057. PubMed ID: 32574991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging Immunotargets and Immunotherapies in Prostate Cancer.
    Montironi R; Santoni M; Sotte V; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Berardi R; Scarpelli M
    Curr Drug Targets; 2016; 17(7):777-82. PubMed ID: 26898309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current role of immunotherapy for the treatment of prostate cancer.
    Porfyris O; Kalomoiris P
    J BUON; 2013; 18(4):809-17. PubMed ID: 24344002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting Immunotherapy: A Focus on Prostate Cancer.
    Cha HR; Lee JH; Ponnazhagan S
    Cancer Res; 2020 Apr; 80(8):1615-1623. PubMed ID: 32066566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization.
    Reimers MA; Slane KE; Pachynski RK
    Curr Urol Rep; 2019 Sep; 20(10):64. PubMed ID: 31482315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving landscape of immunotherapy in advanced prostate cancer.
    Patel VG; Oh WK
    Immunotherapy; 2019 Jul; 11(10):903-912. PubMed ID: 31161846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment].
    Djurhuus SS; Brasso K; Berg KD; Iversen P; Røder MA
    Ugeskr Laeger; 2015 May; 177(20):. PubMed ID: 25967247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for osteosarcoma: Where do we go from here?
    Wedekind MF; Wagner LM; Cripe TP
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in genitourinary malignancies.
    Mehta K; Patel K; Parikh RA
    J Hematol Oncol; 2017 Apr; 10(1):95. PubMed ID: 28434403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
    Wei XX; Fong L; Small EJ
    Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.
    Gulley JL; Madan RA; Heery CR
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.
    Handy CE; Antonarakis ES
    Future Oncol; 2018 Apr; 14(10):907-917. PubMed ID: 29260582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of immunotherapy in castration-resistant prostate cancer (CRPC).
    Suárez C; Morales-Barrera R; Ramos V; Núñez I; Valverde C; Planas J; Morote J; Maldonado X; Carles J
    BJU Int; 2014 Mar; 113(3):367-75. PubMed ID: 23650874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer.
    Redman JM; Steinberg SM; Gulley JL
    J Immunother Cancer; 2018 Sep; 6(1):91. PubMed ID: 30227893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
    Mulders PF; De Santis M; Powles T; Fizazi K
    Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapeutics for the treatment of prostate cancer: a patent landscape based on key therapeutic mechanisms of actions.
    Harris E
    Pharm Pat Anal; 2018 Jan; 7(1):47-57. PubMed ID: 29227196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.